Denosumab

XGEVA®

Overview

Normally, your body is continually breaking down and rebuilding your bone. This helps keep your bones strong.

In people with multiple myeloma, the breakdown and rebuilding of your bones can become unbalanced. Over time, this can cause weak spots in the bones and can lead to serious bone problems.

Denosumab (Xgeva®) works by stopping cells that are breaking down bone from becoming overactive and may interrupt the process of bone breakdown.

SparkCures ID 134
Developed By Amgen
Brand Name Xgeva®
Generic Name Denosumab
Additional Names AMG-162, osteoprotegerin, Xgeva
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.